Group items tagged

Chancellor of the Exchequer, Rachel Reeves, presented the Labour government 's Autumn Budget 2024 in the House of Commons on Wednesday, describing it as "a Budget to fix the foundations of the economy and deliver change by protecting working people, fixing the NHS and rebuilding Britain." The Budget, the first from a Labour government in 14 years, introduces some significant measures to boost small businesses and deliver crucial support to the NHS amid challenging economic conditions. In a move to support businesses, the government has announced a fairer business rates system by permanently lowering the business rates multipliers for retail, hospitality, and leisure (RHL) properties from 2026-27. Additionally, £1.9 billion has been allocated to support small businesses and the high street in 2025-26, including freezing the small business multiplier and providing a 40% relief on RHL property bills, up to a £110,000 cash cap. To repair the public finances and raise funding for public services, the government has decided to increase the employer National Insurance Contributions (NICs) rate by 1.2 percentage points to 15%, with effect from 6 April 2025.

As the general election campaign continues, Labour is set to introduce a series of policies aimed at supporting small businesses. On Saturday, Sir Keir Starmer, alongside shadow chancellor Rachel Reeves and other shadow cabinet ministers, is expected to unveil the party's plans for the sector. Key proposals include an overhaul of the business rates system to enable high street shops to compete with online giants and ensure access to high street banking services by accelerating the establishment of banking hubs. Labour will also commit to addressing the issue of late payment of invoices by requiring large businesses to disclose their payment practices and "revitalise" high streets by tackling antisocial behaviour. Sir Keir described small businesses as "the beating heart of driving growth and creating jobs for local people."

The UK GDP Association has been established as a non-profit organisation, operating as a Community Interest Company (CIC), with a focus on providing a broader support network, particularly for small and medium business enterprises and pharmacy wholesalers. In addition to delivering commercially viable Good Distribution Practice (GDP) consultancy services for simple models with smaller budgets, the association aims to function as a networking platform for Responsible Persons in the UK. As members of the association, companies and individuals can gain multiple benefits that will add value to their business through access to knowledge, discounted training, consultancy services, audit and inspection support, as well as resources like document templates for risk assessments, CAPA, deviations, and more. Moreover, members can enjoy the benefit of a like-minded support network via a dedicated GDP community hub, providing a platform for discussions, seeking advice, and fostering new relationships. "Our mission is to ensure that patient safety, GDP compliance, and excellent quality is paramount in all organisations, regardless of budget," the company said.

The Royal Pharmaceutical Society (RPS)'s new research (YouGov poll) revealed that one in five of UK adults (19%) keep their medicines in the bathroom. The research revealed, "Almost one in two (45%) of UK adult keep their medicines in the kitchen, which could also cause problems. RPS Chief Scientist Professor Parastou Donyai said: "It's important to store your medicines in the right place as this could affect how they work. "Medicines should be stored in a cool, dry place and are particularly affected by heat and moisture. Keeping your medicines in the same place as where you have baths and showers could make your medicines less effective or spoil them. "Instead keep your medicines in another room, for example your bedroom or if you keep them in the kitchen, make sure this is in a kitchen cabinet, away from sources of heat such as the hob, oven or windowsill. If you have small children or pets in the home, always make sure your medicines are kept in a lockable storage box somewhere out of their reach and sight."

Sustainability also brings financial benefits to businesses. This has been proven by Prabjaudt Singh Channa, Director of Priory Pharmacy. Prabjaudt is a proud winner of the Sustainable Pharmacy of the Year 2023, awarded by Pharmacy Business in association with Teva UK. Prabjaudt thanked the award organisers for acknowledging the importance of sustainability within the sector and for recognising his modest endeavours to reduce environmental impact and safeguard future generations. "I just felt really happy and proud of this recognition because originally when I set myself down on this path, I didn't really think anyone would be that bothered about the small changes that we were trying to make and the impact," says Prabjaudt. In addition to his family's background in the field, his passion for chemistry also drove him to pursue a career in pharmacy. He finds being a pharmacy contractor enjoyable because it allows him to be flexible, pursue various interests and shape his professional path.

"Discussions must involve the government on behalf of NHS Scotland, CPS on behalf of the owners, and the PDA as the pharmacists' representative," it said. The association believes that there is a need for discussion and decision-making that listens to and balances the rights and responsibilities of both employers and workers, to generate benefits for individuals, organisations, and society. It added: "Even though Scotland provides the most generous community pharmacy settlement in the UK, recent reports suggest it is not enough for pharmacy owners with CPS's rejection of the latest funding proposal in May. Though the Scottish government found an extra £20M to ease pressures related to medicines price increases, an overall agreement has still not been reached." "The UK-wide chains may be doing less well in the parts of their networks covered by the Westminster government's contract, but the taxpayers and government of Scotland need to be given reassurance that they are in no way subsidising funding shortfalls in England's pharmacy contract." Recently, when LloydsPharmacy's Scotland branches recently came on the market, they appear to have been sold exclusively to existing contractors, including the UK-wide multiple, Rowlands Pharmacy, who have acquired 30 of them. Other small and medium-sized Scottish pharmacy chains have apparently been able to double in size overnight by acquiring branches.

The UK retail sector faced significant challenges in 2024, but 2025 is expected to be an even tougher year for retailers. Nearly 13,500 retail stores permanently shut their doors in the last 12 months -an average of 37 closures each day-according to provisional data from the Centre for Retail Research. This figure represents a notable 28.4 per cent increase from the 10,494 closures recorded in 2023, although it remains below the annual closure rates observed between 2019 and 2022. Independent retailers, typically small businesses with one to five stores, accounted for over 84 per cent of all closures during 2024. This marked a sharp 45 per cent surge in shutdowns for independents compared to the previous year when they were responsible for 74.5 per cent of closures, totalling 7,793 stores. The group's research director, Prof Joshua Bamfield told the Guardian: "The results for 2024 show that although the outcomes for store closures overall were not as poor as in either 2020 or 2022, they are still disconcerting, with worse set to come in 2025."

While Northern Irish business groups has welcomed the certainty a new EU-UK deal on post-Brexit trade rules for the region provided, the pharmaceutical industry too has expressed cautious optimism. In his speech on the Windsor Framework on Monday (February 28) Prime Minister Rishi Sunak said the agreement "delivers a landmark settlement on medicines". "From now on, drugs approved for use by the UK's medicines regulator will be automatically available in every pharmacy and hospital in Northern Ireland," he announced. The National Pharmacy Association's Northern Ireland manager Anne McAlister expressed a sense of cautious optimism. She said: "While the devil may yet be in the detail, the Windsor Framework would appear to be good news for pharmacies in Northern Ireland. It seems to address the main concerns we have expressed about medicines supplies to NI, but we want to examine the small print to ensure the new arrangements meet the needs of our members and the patients they serve.

A new report based on research from pharmacists across England by Sanofi, has called for the introduction of a 'national self-care strategy' to relieve the burden currently faced by health services. The new report, titled 'Driving a self-care revolution in the UK', explores the views of pharmacists, patients and doctors on self-care and the support needed to deliver it more effectively. While self-care policy measures are estimated to increase monetary savings for healthcare systems and national economies by 16%, this report highlights the right tools and resources are not yet in place to enable pharmacists to play a greater role in delivering self-care advice and medicines to patients. "As many as 77% of pharmacists said they would support the creation of a National Self-Care Strategy to provide national leadership on improving understanding of self-care and encourage its use among both patients and clinicians," the report said. According to the report, currently, 33% of pharmacists working for independent or small pharmacy chains do not have the resources to support patients with self-care, alongside their other roles. "To tackle this, close to half (45%) of pharmacists believe greater emphasis by primary care practitioners on the benefits of self-care would leave pharmacists in a better place to support patients. Similarly, 42% believe that training and recruiting more pharmacists would improve their capacity to deliver self-care advice."

One of the long-standing medical mysteries is the diagnosis of diabetes in majority of patients suffering from high blood pressure. The reason for this had been unknown. But now, an international team of universities have made a breakthrough. The research, published online in 'Circulation Research', involved contributions from collaborating scientists in Brazil, Germany, Lithuania, and Serbia, as well as the UK and New Zealand. The important new discovery has shown that a small protein cell glucagon-like peptide-1 (GLP-1) couples the body's control of blood sugar and blood pressure. Professor Julian Paton, a senior author, and director of Manaaki Manawa, The Centre for Heart Research at the University of Auckland, said: "We've known for a long time that hypertension and diabetes are inextricably linked and have finally discovered the reason, which will now inform new treatment strategies." GLP-1 is released from the wall of the gut after eating and acts to stimulate insulin from the pancreas to control blood sugar levels. This was known but what has now been unearthed is that GLP-1 also stimulates a small sensory organ called the carotid body located in the neck.

The Association of Independent Multiple Pharmacies (AIMp) has appointed David Vanns as its non-executive Chairman following the retirement of its long serving Chair Peter Cattee. Vanns will take up the role from April 2023. Cattee, one of the co-founders of AIMp took up the role as its Chairman in 2000. He is also a non-CCA representative on the PSNC. Despite retiring as chairman Cattee will remain on the AIMp board. Commenting on his retirement Cattee said: "It's been my great good fortune to work with almost all of the owners of pharmacy groups throughout England, Scotland and Wales over the years and many other talented people throughout the sector. It's been during a period of increasing consolidation, something which our own business has reflected, and the original founders and Board members Yakub Patel, Kirit Patel, Steve Williams and David Vanns have all been instrumental in shaping pharmacy negotiations to better reflect the views of our natural constituency - pharmacy group owners. A spokesperson for AIMp said: "We thank Peter for his services and dedication to AIMp throughout the years. Our organisation has grown to be a diverse and dynamic organisation representing and supporting pharmacy groups of all sizes, small and large. Our main identity and what unites us in AIMp, irrespective of the size of the pharmacy group, is being Independents, and we are very proud of our identity. We look forward to continuing our work in representing and supporting our members in the best way possible."

Charac, an NHS-integrated one-stop platform for independent community pharmacies, has secured £1 million strategic investment from the Royal Mail Group, enabling its time-saving platform to assist more local pharmacies and patients across the UK to easily manage their prescriptions and consultations online. The company said this new money will enable it to leverage strong levels of trust that pharmacists enjoy within the communities they serve in and will ensure pharmacies remain a cornerstone of vibrant high streets and an invaluable provider of frontline healthcare products and services, including vitally needed consultations. Charac says it is aiming to sign up over 1,000 UK pharmacies in the next 12 months by expanding its geographic footprint beyond current cities, including London, Manchester and Birmingham, and targeting small multiple and independent pharmacies, accounting for almost 40 per cent of the UK's community pharmacy network. The announcement also sees the addition of Stefan Kulik, a managing director at Royal Mail, to the Charac board. Stefan is responsible for leading Royal Mail's expansion into the healthcare industry and brings a breadth of experience, having previously worked in healthcare with companies including Johnson & Johnson.

The Pharmaceutical Defence Association (PDA) has urged health ministers of the UK to take a strict and necessary action against the unnecessary closures of pharmacy. Concerned over the rising number of pharmacy closures, PDA has written an open letter to health secretary Steve Barclay; Robin Swann, health minister for Northern Ireland; Eluned Morgan, minister of health and social services for Wales; and Humza Yousaf, the Scottish health secretary. In its letter, PDA said: "The minister of health must now ensure the regulation of poor business behaviours and be prepared to take over rogue pharmacies, however large their corporate owner may be. If patients' access to NHS services is to be protected from the consequences of avoidable full or part-day pharmacy closures." The association believes it is only a matter of time before serious harm to patients' health will be caused by the decisions of mainly large chains of pharmacies to close some of their branches for all or part of a day, instead of engaging an available pharmacist to cover their agreed opening hours. "While a small number of unforeseen closures have always occurred from time to time in pharmacies for genuine reasons, the indiscriminate scale at which closures have now become commonplace seems to have evolved over the last 20 months."

American global healthcare company, Viatris, has launched a new rapid self-test for qualitative detection of antibodies developed after Covid-19 vaccinations. The firm is going to market the Covid-19 Neutralising IgG Serological self-test, manufactured by PRIMA Lab SA, in the UK market, which would check presence of neutralising antibodies after vaccination. The presence of antibodies indicates that a person has had an immune response to the Covid-19 vaccine, and not that protective immunity has been acquired. The self-test that can be performed easily at home with a small blood sample, delivers results in just 10 minutes and has a recommended retail price of sub £20. After two doses of the Covid-19 vaccine, the self-test has shown a seroconversion rate of 98.3 per cent for the Pfizer vaccine, 98.5 per cent for the AstraZeneca vaccine and 95.2 per cent for the Moderna vaccine. It recommended that the test be performed at least 14 days after completing the vaccination cycle.

As the general election campaign heats up, major political parties - including Labour, the Conservatives, the Liberal Democrats - have released their manifestos, detailing their plans and visions for the future of community pharmacy. While the Conservative Party promises to expand Pharmacy First initiative, Labour pledges support for small businesses, with plans to overhaul the business rates system. The Liberal Democrats' election manifesto commits to developing a fairer and more sustainable long-term funding model for pharmacies. Announcing their plans recently, Prime Minister Rishi Sunak stated that they are investing in community care services to secure the future of the NHS and make healthcare more accessible. The Conservatives plan to fund these initiatives by cutting NHS managerial positions back to pre-pandemic levels and halving the government's management consultancy expenditure.

A Orthodontic treatment should be carried out by qualified professionals round this time five years ago there was a surge in the reporting of people performing DIY orthodontics on themselves in their own homes. Mainstream media reported that video tutorials had emerged online with instructions on using small elastic bands to adjust teeth positions. What followed were some horrendous pictures of irreparable damage to people's teeth and gums. The trend escalated to a point where in 2017, the American Dental Association revealed that 13 per cent of patients had tried some kind of DIY teeth straightening appliance that had backfired. Now, we are seeing the situation further evolve, with private companies offering DIY orthodontic treatment under the term 'direct-to-consumer' orthodontics. The Oral Health Foundation is becoming increasingly concerned with the rise of the DIY orthodontic market and the potential harmful consequences it could have for millions of consumers.

PCCA Limited has issued a recall for its Ketamine 50mg/5ml and 100mg/5ml oral solutions after a small number of bottles have been observed to contain crystalline material. The company said it is recalling impacted batches from patients, pharmacies and hospitals as a precautionary measure. "This recall is being issued as a company-led medicines recall, as this product is only supplied to a small number of customers and the company has traceability of the onward distribution by their customers to patients directly," the MHRA said in an alert. Check the website.

A new report published by the NHS Business Services Authority (NHSBSA) reveals that 24,300 dentists performed NHS dental activity in England in 2023/24, marking a 0.4 per cent rise from the previous year's 24,227. However, this figure represents a 1.5 per cent decrease from 24,700 dentists with NHS activity in 2019/20. The report covers NHS dental activity and the NHS dental workforce in England from 2019/20 to 2023/24. It is the first release from NHSBSA following the transition from NHS England, which previously issued the report. There were 34 million courses of dental treatment in England for 2023/24, a 4.3 per cent increase from 2022/23. The total units of dental activity (UDAs) rose by 3.4 per cent to 73 million.

Britain's GlaxoSmithKline will receive $1.25 billion (about £921 million) from Gilead Sciences as part of a settlement between its HIV medicines unit and the US-based drugmaker, ending a long-drawn patent dispute. The settlement, announced by GSK on Tuesday (February 1), relates to Gilead's antiretroviral drug Biktarvy, a medicine used to check the AIDS-causing virus, which GSK said in 2018 infringed on its unit ViiV Healthcare's dolutegravir and other similar compounds. HIV medicines developed by ViiV, in which Pfizer and Japan's Shionogi also hold small stakes, are a major part of GSK's plan to support its lagging pharmaceuticals business as it readies to spin off its consumer healthcare arm. The payment is expected to be made in the first quarter this year, London-listed GSK said. Gilead will also pay a 3 per cent royalty until 2027 on sales of Biktarvy and on future US sales of any product containing its main component.

Thousands of lung cancer patients in England will benefit from a ground-breaking new drug that can reduce the risk of relapse. This follows a deal brokered by NHS England and approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for atezolizumab therapy to treat non-small cell lung cancer (NSCLC). More than 850 patients are expected to be eligible for the drug in the first year, rising to more than 1000 in the third year. It is the first immunotherapy approved for patients with early-stage NSCLC who have undergone surgery and chemotherapy. Clinical trials have shown that atezolizumab can reduce the risk of cancer relapse or death by 34 per cent in patients with early-stage NSCLC.